Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2008
02/21/2008WO2008019871A2 Novel salts of the active substance rasagiline
02/21/2008WO2008019825A1 Use of tricyclic indole derivatives for the treatment of muscular diseases
02/21/2008WO2008019823A2 Use of certain chemical compounds for the inhibition of the peptidyl-prolyl cis/trans isomerase activity of cyclophilins
02/21/2008WO2008019820A2 Crystal form of epothilone b and use in pharmaceutical compositions
02/21/2008WO2008019785A2 Transdermal application of triazines for controlling coccidia infections
02/21/2008WO2008019769A1 Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10- hydroxydecy l)-1,4-benzoquinone
02/21/2008WO2008019690A1 Substituted acetylenic compounds useful for the treatment of diseases
02/21/2008WO2008019594A1 Agmatine sulfate dihydrate and its medicinal use
02/21/2008WO2008019572A1 Meptazinol biligand derivatives and/or their salts, preparation method and uses thereof
02/21/2008WO2008019486A1 Nucleic acid modulation of toll-like receptor-mediated immune stimulation
02/21/2008WO2008019477A1 Viral polymerase inhibitors
02/21/2008WO2008019431A1 Method and compositions for simultaneously regulating memory and mood
02/21/2008WO2008006714A3 Improvements relating to biocidal compositions
02/21/2008WO2008006099A3 Treatment of psychiatric disorders
02/21/2008WO2008006043A3 1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents
02/21/2008WO2008005676A3 Injectable collagen material
02/21/2008WO2008005577A3 Compositions of polyphenols and methods of use
02/21/2008WO2008005217A3 Iron(ii)-containing treatments for hyperphosphatemia
02/21/2008WO2008002471A3 Erosion-stabilized bioadhesive polymers functionalized or blended with catechol and derivatives thereof
02/21/2008WO2008001294A3 High dose oral pharmaceutical compositions of artemether and lumefantrine
02/21/2008WO2008001240A3 Transdermal delivery of oleocanthal for relief of inflammation
02/21/2008WO2008000951A3 Urea derivatives of tropane, their preparation and their therapeutic application
02/21/2008WO2008000743A3 Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
02/21/2008WO2007150064A3 METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE
02/21/2008WO2007150026A3 Purinone derivatives as hm74a agonists
02/21/2008WO2007149568A3 N- (4-chl0r0-3-methyl-5-is0xaz0lyl) -2- [2-methyl-4, 5- (methylenedioxy) phenylacetyl] -thiophene-3-sulfonamide
02/21/2008WO2007149512A3 Peptide epoxyketones for pr0teas0me inhibition
02/21/2008WO2007149451A3 Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors
02/21/2008WO2007149448A3 Pyrazinones as cellular proliferation inhibitors
02/21/2008WO2007149427A3 Tyrosine kinase inhibitors
02/21/2008WO2007149277A3 Substituted 8-[6-amino-3-pyridyl]xanthines
02/21/2008WO2007147128A3 Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
02/21/2008WO2007146981A3 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha
02/21/2008WO2007146867A3 Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
02/21/2008WO2007146831A3 Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
02/21/2008WO2007146805A3 Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
02/21/2008WO2007146768A3 Compounds for the treatment of metabolic disorders
02/21/2008WO2007146759A3 Novel mch receptor antagonists
02/21/2008WO2007146311A3 Compositions and methods for protecting newborn lung development with ethyl nitrite
02/21/2008WO2007146116A3 Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
02/21/2008WO2007144501A3 Use of a vasopeptidase inhibitor for the treatment of pulmonary arterial hypertension
02/21/2008WO2007144085A8 Opioid combination wafer
02/21/2008WO2007143507A3 Preparation and utility of substituted erythromycin analogs
02/21/2008WO2007143081A3 Therapeutic agents for the treatment of lymphoid malignancies
02/21/2008WO2007142546A3 Sustained release coated tablet with precisely regulated release profile
02/21/2008WO2007136746A3 Macrocyclic compounds and their uses as stearoyl-coa desaturase
02/21/2008WO2007136692A3 Crystalline forms of 5-chloro-6- (2, 6-difluoro-4- [3- (methylamino) propoxy] phenyl)-n-((1s)-2, 2, 2,-trifluoro-1-methylethyl] [1,2,4] triazolo [1,5-a] pyrimidin-7-amine salts
02/21/2008WO2007135078A3 Borrelidin derivatives as antiproliferative agents and angiogenesis inhibitors
02/21/2008WO2007134161A3 Compositions and methods for inhibiting expression of the pcsk9 gene
02/21/2008WO2007130860A3 Constrained compounds as cgrp-receptor antagonists
02/21/2008WO2007130509A9 Pyrroloquinoline quinones and use thereof
02/21/2008WO2007129066A8 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer
02/21/2008WO2007128088A3 Use of n-aminoimidazole cytoprotective compounds for treating cell death and/or gsk-3 mediated diseases
02/21/2008WO2007127012B1 Antifungal agents
02/21/2008WO2007124308A3 Methods and compositions for modulation of blood-neural barrier
02/21/2008WO2007121495A3 Method for diagnosing cardiovascular diseases
02/21/2008WO2007121389A3 4,4-disubstituted piperidine derivatives as nk-i and serotonin transporter inhibitors
02/21/2008WO2007117400A3 Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
02/21/2008WO2007112065A3 Methods for treating cognitive and other disorders
02/21/2008WO2007110761A3 Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof
02/21/2008WO2007110243A8 Medicament, cosmetic or food product comprising an indol compound, the use thereof and the method of isolation thereof from sauerkraut
02/21/2008WO2007110152A3 Polylactide nanoparticles
02/21/2008WO2007106886A3 Fluorinated carbohydrates and their use in tumor visualization, tissue engineering, and cancer chemotherapy
02/21/2008WO2007101935A3 Novel heterocyclic cycloalkyl derivatives, method for the preparation thereof, and pharmaceutical compositions containing the same
02/21/2008WO2007101213A3 Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
02/21/2008WO2007100822A3 Fluvastatin sodium pharmaceutical compositions
02/21/2008WO2007095627A3 Pqs: a new hydrotrope for solubilizing lipophilic compounds in water
02/21/2008WO2007092609A3 Method for treating peripheral arterial disease with zinc finger proteins
02/21/2008WO2007089577A3 Method of reversing, preventing, delaying or stabilizing soft tissue calcification
02/21/2008WO2007087427A3 Thiazole and thiadiazole compounds for inflammation and immune-related uses
02/21/2008WO2007087068A3 Inhibitors of tyrosine kinases and uses thereof
02/21/2008WO2007086541A3 Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
02/21/2008WO2007086079A3 Sustained release dosage form of phenothiazine derivatives containing channelizer
02/21/2008WO2007079312A3 Compositions and methods for treating actin-mediated medical conditions
02/21/2008WO2007075980A3 Lansoprazole orally disintegrating tablets
02/21/2008WO2007075809A3 Oxazoloisoquinoline derivatives as thrombin receptor antagonists
02/21/2008WO2007075092A8 New derivatives of epirubicin, their medicinal application and pharmaceuticals acceptable forms of drugs
02/21/2008WO2007070433A3 2-arylthiazole derivatives as cxcr3 receptor modulators
02/21/2008WO2007070425A3 Use of low-dose ladostigil for neuroprotection
02/21/2008WO2007068934A3 Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
02/21/2008WO2007067770A3 Pharmaceutical compositions and methods for improved bacterial eradication
02/21/2008WO2007067621A3 Biocompatible surgical compositions
02/21/2008WO2007049796A3 Resveratrol and/or grape leaf extract as i. a. endurance improver, anti-aging agent, muscle strength improver
02/21/2008WO2007042010A3 Synergistic pharmaceutical composition containing a peptide with 2 to 5 amino acids
02/21/2008WO2007038241A8 Modulation of mesenchymal and metastatic cell growth
02/21/2008WO2007027560A8 Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
02/21/2008WO2007021168A8 Sublingual solid pharmaceutical formulations containing meloxicam
02/21/2008WO2007014250A8 Abl kinase inhibition
02/21/2008WO2007010294A8 Use of delmopinol in the treatment of acne
02/21/2008WO2006134317A8 Oxadiazole derivatives as dgat inhibitors
02/21/2008WO2006130493A8 Heterocycles useful as modulators of ion channels
02/21/2008WO2006073458A3 Oligonucleotides comprising a c5-modified pyrimidine
02/21/2008WO1999059544A9 Orally disintegrable tablets
02/21/2008US20080046089 Spine distraction implant and method
02/21/2008US20080046088 Spine distraction implant and method
02/21/2008US20080045959 Spine distraction implant and method
02/21/2008US20080045721 Thiazole-oxime chemical intermediates to cephalosporin-linked vancomycin derivatives which have use against antibiotic-resistant bacteria including methicillin-resistant Staphylococci aureus (MRSA)
02/21/2008US20080045713 Tetrahydroisoquinolinedione derivative intermediates for the hemisynthesis of ecteinascidin or other tetrahydroisoquinolinephenol compounds
02/21/2008US20080045709 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
02/21/2008US20080045605 Image Quality in the Eye